Association of Growth and Differentiation Factor 15 in Rheumatoid Arthritis

References

• Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305–317. doi:10.1016/S0140-6736(20)32341-2
   PubMed Web of Science ®Google Scholar
• Dedmon LE. The genetics of rheumatoid arthritis. Rheumatology. 2020;59(10):2661–2670. doi:10.1093/rheumatology/keaa232
   PubMed Web of Science ®Google Scholar
• Lodi RS, Yu B, Xia L, Liu F. Roles and Regulation of Growth differentiation factor-15 in the Immune and tumor microenvironment. Hum Immunol. 2021;82:937–944. doi:10.1016/j.humimm.2021.06.007
   PubMed Web of Science ®Google Scholar
• Wang D, Day EA, Townsend LK, Djordjevic D, Jørgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592–607. doi:10.1038/s41574-021-00529-7
   PubMed Web of Science ®Google Scholar
• Wischhusen J, Melero I, Fridman WH. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951. doi:10.3389/fimmu.2020.00951
   PubMed Web of Science ®Google Scholar
• Ye D, Liu B, He Z, et al. Assessing the associations of growth differentiation factor 15 with rheumatic diseases using genetic data. Clin Epidemiol. 2021;13:245–252. doi:10.2147/CLEP.S305024
   PubMed Web of Science ®Google Scholar
• Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003;9(7):2642–2650.
   PubMed Web of Science ®Google Scholar
• Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst. 2004;96(16):1248–1254. doi:10.1093/jnci/djh227
   PubMedGoogle Scholar
• Neogi T, Aletaha D, Silman AJ, et al. The 2010 American college of Rheumatology/European league against rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010;62(9):2582–2591. doi:10.1002/art.27580
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, Van leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48. doi:10.1002/art.1780380107
   PubMed Web of Science ®Google Scholar
• Xu WD, Su LC, He CS, Huang AF. Plasma interleukin-38 in patients with rheumatoid arthritis. Int Immunopharmacol. 2018;65:1–7. doi:10.1016/j.intimp.2018.09.028
   PubMed Web of Science ®Google Scholar
• Xu WD, Wu Q, He YW, et al. Gene polymorphisms of LGALS2, LGALS3 and LGALS9 in patients with rheumatoid arthritis. Cell Immunol. 2021;368:104419. doi:10.1016/j.cellimm.2021.104419
   PubMed Web of Science ®Google Scholar
• Esalatmanesh K, Fayyazi H, Esalatmanesh R, Khabbazi A. The association between serum levels of growth differentiation factor-15 and rheumatoid arthritis activity. Int J Clin Pract. 2020;74(9):e13564. doi:10.1111/ijcp.13564
   PubMed Web of Science ®Google Scholar
• Tanrıkulu O, Sarıyıldız MA, Batmaz İ, et al. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. Acta Reumatol Port. 2017;42(1):66–72.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Zhang T, Guo J, Peng YF, Wei YS. The association of growth differentiation factor-15 gene polymorphisms with growth differentiation factor-15 serum levels and risk of ischemic stroke. J Stroke Cerebrovasc Dis. 2017;26(10):2111–2119. doi:10.1016/j.jstrokecerebrovasdis.2017.04.031
   PubMed Web of Science ®Google Scholar
• Chen Z, Xie F, Ma G, Feng Y, Qian Q, Liu N. Study of the association between growth differentiation factor 15 gene polymorphism and coronary artery disease in a Chinese population. Mol Biol Rep. 2011;38(8):5085–5091. doi:10.1007/s11033-010-0655-4
   PubMed Web of Science ®Google Scholar
• Wang J, Li W, Wang Y, et al. The H6D genetic variation of GDF15 is associated with genesis, progress and prognosis in colorectal cancer. Pathol Res Pract. 2015;211(11):845–850. doi:10.1016/j.prp.2015.08.004
   PubMed Web of Science ®Google Scholar
• Hayes VM, Severi G, Southey MC, et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1223–1225. doi:10.1158/1055-9965.EPI-06-0063
   PubMed Web of Science ®Google Scholar
• Ärlestig L, Rantapää-Dahlqvist S. Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease. J Rheumatol. 2012;39(5):939–945. doi:10.3899/jrheum.111336
   PubMed Web of Science ®Google Scholar
• Amaya-Amaya J, Rojas-Villarraga A, Molano-Gonzalez N, Montoya-Sánchez L, Nath SK, Anaya JM. GDF15(MIC1) H6D polymorphism does not influence cardiovascular disease in a latin American population with rheumatoid arthritis. J Immunol Res. 2015;2015:270763. doi:10.1155/2015/270763
   PubMed Web of Science ®Google Scholar
• Xu WD, Liu XY, Su LC, Huang AF. Association of MASP2 levels and MASP2 gene polymorphisms with systemic lupus erythematosus. J Cell Mol Med. 2020;24(18):10432–10443. doi:10.1111/jcmm.15656
   PubMed Web of Science ®Google Scholar
• Fairlie WD, Russell PK, Wu WM, et al. Epitope mapping of the transforming growth factor-beta superfamily protein, macrophage inhibitory cytokine-1 (MIC-1): identification of at least five distinct epitope specificities. Biochemistry. 2001;40(1):65–73. doi:10.1021/bi001064p
   PubMed Web of Science ®Google Scholar
• Wang X, Chrysovergis K, Bienstock RJ, Shim M, Eling TE. The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo. Prostate. 2012;72(6):677–689. doi:10.1002/pros.21471
   PubMed Web of Science ®Google Scholar
• Wang X, Yang X, Sun K, et al. The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci. 2009;118(2):137–145. doi:10.1042/CS20080637
   Web of Science ®Google Scholar
• Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. doi:10.1371/journal.pone.0117952
   PubMed Web of Science ®Google Scholar
• Lee SE, Kang SG, Choi MJ, et al. Growth differentiation factor 15 mediates systemic glucose regulatory action of t-helper type 2 cytokines. Diabetes. 2017;66(11):2774–2788. doi:10.2337/db17-0333
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Newton D, Bragazzi N, Wittmann M, McGonagle D. Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis. Semin Immunol. 2021;101520. doi:10.1016/j.smim.2021.101520
   PubMed Web of Science ®Google Scholar
• Moschovaki-Filippidou F, Steiger S, Lorenz G, et al. Growth differentiation factor 15 ameliorates anti-glomerular basement membrane glomerulonephritis in mice. Int J Mol Sci. 2020;21(19):6978. doi:10.3390/ijms21196978
   PubMed Web of Science ®Google Scholar
• Bakheet SA, Alrwashied BS, Ansari MA, et al. CXC chemokine receptor 3 antagonist AMG487 shows potent anti-arthritic effects on collagen-induced arthritis by modifying B cell inflammatory profile. Immunol Lett. 2020;225:74–81. doi:10.1016/j.imlet.2020.06.014
   PubMed Web of Science ®Google Scholar
• Bakheet SA, Ansari MA, Nadeem A, et al. CXCR3 antagonist AMG487 suppresses rheumatoid arthritis pathogenesis and progression by shifting the Th17/Treg cell balance. Cell Signal. 2019;64:109395. doi:10.1016/j.cellsig.2019.109395
   PubMed Web of Science ®Google Scholar